A Clinical Trial of FX301 (XEN402 Formulated for Extended Release from a Thermosensitive Hydrogel) for the Treatment of Post-Operative Pain
Latest Information Update: 16 Sep 2019
Price :
$35 *
At a glance
- Drugs Funapide (Primary)
- Indications Postoperative pain
- Focus Adverse reactions; Proof of concept
- Sponsors Flexion Therapeutics
- 16 Sep 2019 New trial record
- 09 Sep 2019 According to a Flexion Therapeutics media release, FX301 is anticipated to enter this clinical trial in 2021.
- 09 Sep 2019 According to a Flexion Therapeutics media release, Flexion Therapeutics and Xenon Pharmaceuticals have entered into a definitive agreement that provides Flexion with the global rights to develop and commercialize XEN402, for the management of post-operative pain.